What are you searching for?

21.02.2020 | Tracker

HCPs excited for Erleada label expansion in prostate cancer

By Laura McIntyre

Janssen’s Erleada (apalutamide) approval for expanded use in patients with metastatic hormone-sensitive prostate cancer sparked excitement last month among healthcare professionals (HCP) online. They shared the news on social media often linking to Janssen’s press release on Business Wire. In total, Erleada’s approval was mentioned 34 times.

https://twitter.com/amerseburger/status/1222493915200311296

The second most mentioned product, relating to its EMA approval, was a conditional marketing authorization for Roche’s Polivy (polatuzumab vedotin), in combination with rituximab and bendamustine for treating patients with relapsed or refractory diffuse large B-cell lymphoma. Graham Collins, a lymphoma specialist in the Oxford Cancer and Haematology Centre, wondered how it will perform in the NICE appraisal process.

https://twitter.com/graham74GC/status/1220598097975369728

Besides the various medicines discussed, cardiologists also enthusiastically posted about Abbott’s world first transcatheter mitral valve, Tendyne. HCPs shared news of its approval, sharing the article by Diagnostic and Interventional Cardiology and reposting Abbott’s tweet.

https://twitter.com/AbbottNews/status/1222927504694022144
https://twitter.com/cpietranton/status/1222963082978381826

We are tracking the HCP reaction to EMA approvals and related topics each month. You can keep up to date with this and other pharmaceutical tracking updates, including FDA drug approvals, within the Tracking section of CREATION Knowledge or by signing up our monthly newsletter.


READ LAST MONTH’S EMA APPROVAL TRACKER:

https://creation.co/knowledge/ema-approvals-tracker-hcps-anticipating-2020-approvals/

Methodology notes:

  • Data for this research was analysed from the online Twitter conversations of HCPs talking about EMA approvals in English language (all other languages are available), between 15 January and 14 February, 2020.
  • Between 15 January and 14 February, 2020, 84 HCPs posted relating to EMA approvals 89 times all over the world.

View all articles >

Meet the Author

Laura McIntyre

As a Health Strategy Consultant Laura combines her passion for people with skills in project management and communications as she supports our clients through every step during and following a project. Outside work Laura is passionate about music, previously traveling the world as a professional opera singer.

Suggested next


15.03.2018 | Article

Hot topic in Cancer: What US doctors discuss about Immuno-oncology

Hot topic in Cancer: What US doctors discuss about Immuno-oncology

By Lara Meyer

17.04.2019 | Article

We’re studying what healthcare professionals think about pancreatic cancer treatment: here’s why

We’re studying what healthcare professionals think about pancreatic cancer treatment: here’s

By Laura McIntyre

View all articles >